Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
QuintilesIMS
McKinsey
Chinese Patent Office
Cerilliant
Boehringer Ingelheim
US Army
Baxter
UBS

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,793,931

« Back to Dashboard

Which drugs does patent 6,793,931 protect, and when does it expire?

Patent 6,793,931 protects ULESFIA and is included in one NDA.
Summary for Patent: 6,793,931
Title: Ectoparasite asphyxiator compositions and methods for their applications
Abstract:Water-soluble or water-dispersible, substantially air-impermeable, pharmacologically acceptable, liquid barrier compositions for treating ectoparasite infestations on animal skin and hair, wherein the compositions contain at least one monohydric aralkyl alcohol to prevent the ectoparasites from closing their respiratory systems.
Inventor(s): Precopio; Michael J (Collegeville, PA)
Assignee: Summers Laboratories, Inc. (Collegeville, PA)
Application Number:10/195,048
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,793,931
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Device;

Drugs Protected by US Patent 6,793,931

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TOPICAL TREATMENT OF LICE INFESTATIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,793,931

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,294,342 Ectoparasite asphyxiator compositions and methods for their application ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Baxter
Teva
Chubb
Merck
Queensland Health
McKesson
Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.